home / stock / nvct / nvct news

NVCT News and Press, Nuvectis Pharma Inc. From 12/18/23

Stock Information
Company Name: Nuvectis Pharma Inc.
Stock Symbol: NVCT
Market: NASDAQ
Website: nuvectis.com
Menu
NVCT NVCT Quote NVCT Short NVCT News NVCT Articles NVCT Message Board
Get NVCT Alerts

News, Short Squeeze, Breakout and More Instantly...
NVCT - Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma

Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trial The Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 Ame...
NVCT - Expected earnings - Nuvectis Pharma Inc.

Nuvectis Pharma Inc. (NVCT) is expected to report $-0.38 for Q3 2023

NVCT - Nuvectis Pharma GAAP EPS of -$0.37

2023-11-08 09:04:52 ET More on Nuvectis Pharma Nuvectis: Early Stage Company That's Low On Cash Nuvectis gains on FDA orphan drug status for lead asset Seeking Alpha’s Quant Rating on Nuvectis Pharma Historical earnings data for Nuvectis Pharma ...

NVCT - Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid Tumors NXP800 Granted Orphan Drug Designation for the Treatment of Cholangiocarc...
NVCT - Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer

Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, to...

NVCT - Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, t...

NVCT - Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, t...
NVCT - Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, t...

NVCT - Nuvectis: Early Stage Company That's Low On Cash

2023-09-06 08:03:53 ET Summary Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT als...

NVCT - Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, t...
Previous 10 Next 10